Skip to content

Repligen RGEN Q4 2024 Annual earnings

Reported February 20, 2025 · Before market open

Revenue$167.5MBeat by $3.5M
EPS$0.44Beat by $0.03
Revenue estimate$164.1M
EPS estimate$0.41

Next report

Oct 27, 2026 (in 3 months)
Revenue estimate$206.9M
EPS estimate$0.46

Financials

Q4 2024

Income statement

See full
Net income-$33.9M

Balance sheet

See full
Cash & equivalents$757.4M+0.8%
Total debt$686.2M+332%
Total equity$2.0B+0.4%
Total assets$2.8B-0.1%

Cash flow

See full
Operating cash flow$39.2M+34.8%
CapEx$5.5M-50.0%
Free cash flow$33.6M+87.1%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$8.06B-19.6%
Enterprise value$7.99B-15.4%

Returns & leverage

See full
Return on equity-1.5%
Debt / equity0.3×+0.3×
Current ratio8.4×+1.7×

Segments

By product

See full
Proteins Products$18.6M-28.1%
Process Analytics Products$14.8M+4.4%
Royalty$153.0K-43.8%

Versus estimates

Ask the moment Repligen reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Repligen report Q4 2024 earnings?
Repligen (RGEN) reported Q4 2024 earnings on February 20, 2025 before market open.
What were Repligen's Q4 2024 revenue and EPS?
Repligen reported revenue of $167.5M and eps of $0.44 for Q4 2024.
Did Repligen beat estimates in Q4 2024?
Revenue beat the consensus estimate of $164.1M by $3.5M. EPS beat the consensus estimate of $0.41 by $0.03.
Where can I find Repligen's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-038999) directly on SEC EDGAR. The filing index links above go to sec.gov.